MabionCD20 – Unlocking New Opportunities
- Mabion and Oddifact have partnered to repurpose MabionCD20 specifically for the treatment of rare orphan diseases. Our project is now being reactivated as an innovative drug, shifting away from the crowded biosimilar market.
- Mabion brings extensive experience in biologics manufacturing, including upstream and downstream technology platforms.
- Oddifact SAS provides an AI-powered platform (S.A.V.E.) to identify and design new therapeutic indications for existing biologics.
MabionCD20 Reactivation
Mabion main asset, MabionCD20, is a monoclonal antibody as a rituximab-based biologic drug. It was originally designed as a biosimilar candidate for MabThera and Rituxan, two established anti-CD20 therapies used in many diseases, including lymphoma and rheumatoid arthritis. The project did not reach the registration stage in its initial form as a biosimilar. However, it represents a highly mature scientific asset because it is based on one of the most clinically validated therapeutic targets in modern immunology and hematology: the CD20 antigen.
Mabion has built substantial technical readiness around MabionCD20, including cell line development, upstream and downstream bioprocessing, drug substance manufacturing know-how, and advanced analytical methods.
Changes in the FDA Regulatory Environment
Mabion’s new strategic focus for MabionCD20 centers on the rare diseases treatments within the United States, a pivot that is highly justified by the current regulatory landscape. FDA are increasingly allowing wider access to orphan drugs for patients. This approach is supported by the guidelines, which have made the pathway for such therapies significantly more business-friendly by offering a framework for accelerated development.
For Mabion, this creates an opportunity to move MabionCD20 from a historic biosimilar-development project into a targeted, innovative orphan drug programme. The goal is not merely to revisit a past asset. It is to apply Mabion’s biologics expertise to an indication with unmet medical need and limited patient populations. In this context, biomarker-based development and accelerated regulatory dialogue may make a shorter and more efficient development pathway possible. The drug already possesses two FDA Orphan Drug Designations (ODD) for:
A primary goal of this strategy is to democratize effective treatments. This means broadening access to innovative drugs. It also means helping them reach patients as quickly as possible. Following an FDA acceptance through initial consultations, the project can move into an accelerated registration mode. It can also follow a streamlined registration process. This pathway is designed for individualized and rare therapies. It allows development to proceed with smaller patient populations and targeted evidence packages. It may also use biomarkers to establish efficacy, accelerating the path from discovery to commercial availability.
The Role of Oddifact SAS in the MabionCD20 Development
Oddifact SAS is an innovative biotech platform. It is dedicated to accelerating therapeutic innovation in rare diseases. It does so through strategic biologics repositioning and advanced AI-driven regulatory intelligence. Oddifact’s role in the MabionCD20 project is justified by the strong complementarity between the two companies. Mabion contributes deep experience in biologics development, manufacturing, analytics, and regulatory-quality documentation. Oddifact contributes technology and know-how for identifying, designing, and predicting high-potential rare disease indications for biologics. Oddifact’s platform approach is based on extensive clinical regulatory data. It transforms this data into actionable therapeutic and development assets. It also creates regulatory assets that can support further drug development.
The platform helps Mabion evaluate MabionCD20’s potential. It can identify where the asset may have the strongest scientific fit. It can also assess its commercial fit. This is particularly valuable in orphan diseases. In these indications, the right choice of indication, endpoint strategy, and clinical-trial design is critical. A well-prepared FDA briefing package can help the project advance efficiently and avoid unnecessary uncertainty.
Prepared by:
Marketing Specialist
For further reading
- FDA. Guidance Documents for Rare Disease Drug Development. 2026.
- EMA. Development of medicines for rare diseases. 2018.
- FDA. FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases. 2026.
- Brooks K. Mabion Enters Rare Disease Collaboration with Oddifact. Contract Pharma. 2026.